Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance

Figure 2

The progression-free survival (PFS) of patients with extramedullary disease at diagnosis and at relapse. The median duration of PFS of patients in EMD-1 and EMD-2 was 20 months and 14 months, respectively ().